TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33688640

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33688834

Group type: EXPERIMENTAL
Intervention: Tri/tetracyclic antidepressants + SGA
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: FGA + MSA
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: FGA
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: SNRI + SGA
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Lithium + MSA
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Lithium + SGA
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: SNRI
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: No drug
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Bupropion + SSRI
Number of subjects: 529359

Group type: EXPERIMENTAL
Intervention: Psychotherapy alone (without medication)
Number of subjects: 529359
Study: 33688844

Group type: EXPERIMENTAL
Intervention: Web-based wellness platform (My Viva Plan)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no access to MVP)
Number of subjects: 97
Study: 33688857

Group type: EXPERIMENTAL
Intervention: COVID-19 lockdown period
Number of subjects: 76
Study: 33689033

Group type: EXPERIMENTAL
Intervention: Post-PLA
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Post-EV+
Number of subjects: 7

Group type: COMPARATOR
Intervention: Post-EV-
Number of subjects: 7
Study: 33689063

Group type: EXPERIMENTAL
Intervention: High-sodium (HS) diet (300 mEq/day) for 6 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-sodium (LS) diet (10 mEq/day) for 6 days
Number of subjects: 14
Study: 33689985

Group type: EXPERIMENTAL
Intervention: Follow-up testing of borderline SARS-CoV-2 patients using rRT-PCR
Number of subjects: 107

Group type: COMPARATOR
Intervention: Borderline SARS-CoV-2 test results
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall positive SARS-CoV-2 samples in the follow-up group
Number of subjects: 107
Study: 33691074

Group type: EXPERIMENTAL
Intervention: Mobile Teledermatology
Number of subjects: 0
Study: 33691182

Group type: EXPERIMENTAL
Intervention: Short Messages
Number of subjects: 0
Study: 33691262

Group type: EXPERIMENTAL
Intervention: GLS-010 at a dose of 240 mg Q2W
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: GLS-010 at doses of 1, 4, or 10 mg/kg Q2W; 240 mg Q3W or Q2W
Number of subjects: 289
Study: 33691305

Group type: EXPERIMENTAL
Intervention: Chronic opioid use
Number of subjects: 22844

Group type: EXPERIMENTAL
Intervention: Other drug classes
Number of subjects: 22844

Group type: EXPERIMENTAL
Intervention: TADL
Number of subjects: 22844
Study: 33691309

Group type: EXPERIMENTAL
Intervention: Normal QRS axis in newborns
Number of subjects: 12317

Group type: COMPARATOR
Intervention: Sex (boys vs girls)
Number of subjects: 12317

Group type: COMPARATOR
Intervention: Gestational age (GA)
Number of subjects: 12317

Group type: COMPARATOR
Intervention: Infant size
Number of subjects: 12317

Group type: EXPERIMENTAL
Intervention: QRS axis intervals
Number of subjects: 12317
Study: 33691480

Group type: EXPERIMENTAL
Intervention: Evinacumab, dosage and duration not specified
Number of subjects: 0
Study: 33691765

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation (LMWH or UFH)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Standard care (thromboprophylactic doses of LMWH or UFH)
Number of subjects: 462
Study: 33692132

Group type: EXPERIMENTAL
Intervention: siBcl2L12-SNAs (NU-0129) administered intravenously at a dose corresponding to 1/50th of the no-observed-adverse-event level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: siBcl2L12-SNAs (NU-0129) administered intravenously
Number of subjects: 0
Study: 33692676

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33692727

Group type: EXPERIMENTAL
Intervention: Communication skills training for radiographers; details on dosage and duration not available
Number of subjects: 0
Study: 33693009

Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard oxygen therapy)
Number of subjects: 0
Study: 33693520

Group type: EXPERIMENTAL
Intervention: eREE-CKD equation
Number of subjects: 300
Study: 33693709

Group type: EXPERIMENTAL
Intervention: GDM with depressive symptoms
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: NGT with depressive symptoms
Number of subjects: 1843

Group type: COMPARATOR
Intervention: GDM without depressive symptoms
Number of subjects: 1843

Group type: COMPARATOR
Intervention: NGT without depressive symptoms
Number of subjects: 1843
Study: 33693736

Group type: EXPERIMENTAL
Intervention: Multiple hormonal and metabolic deficiency syndrome (MHDS)
Number of subjects: 480

Group type: COMPARATOR
Intervention: No multiple hormonal and metabolic deficiency syndrome (NO-MHDS)
Number of subjects: 480
Study: 33693776

Group type: EXPERIMENTAL
Intervention: 20 mg gliclazide
Number of subjects: 16
Study: 33693781

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS)
Number of subjects: 9
Study: 33693813

Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 961

Group type: COMPARATOR
Intervention: No Vitamin D supplements
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Blood collection in summer or fall
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Nonfall birth season
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to higher 25(OH)D
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Higher dietary intake of Vitamin D
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Greater waist circumference (among black children only)
Number of subjects: 961
Study: 33693943

Group type: EXPERIMENTAL
Intervention: Anti-HIV antibodies
Number of subjects: 0
Study: 33693990

Group type: EXPERIMENTAL
Intervention: Eculizumab (off-label use in 44% of cases)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 152
Study: 33694071

Group type: EXPERIMENTAL
Intervention: COVID-19 exposure
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: COVID-19 illness
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: Job burnout
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: Physical and emotional distress
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: Risk of COVID-19 illness by race/ethnicity
Number of subjects: 14600
Study: 33694084

Group type: EXPERIMENTAL
Intervention: Lysophosphatidylethanolamine acyltransferase (LPEAT) levels in patients with severe CAP (SCAP)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: LPEAT levels in patients stratified by PSI and CURB-65 scores
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: LPEAT as a predictor of SCAP in patients with CAP
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: LPEAT in predicting 30-day mortality rate in patients with CAP
Number of subjects: 267
Study: 33694093

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 33694122

Group type: EXPERIMENTAL
Intervention: Men (age group not specified)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Women (age group not specified)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Women under 55 years
Number of subjects: 211

Group type: COMPARATOR
Intervention: Men under 55 years
Number of subjects: 211

Group type: COMPARATOR
Intervention: Overall population (men and women)
Number of subjects: 211
Study: 33694257

Group type: EXPERIMENTAL
Intervention: Lenalidomide (starting dose 2 mg/kg/day on days 1-21 of each 28-day cycle for a maximum of 12 cycles)
Number of subjects: 17
Study: 33694368

Group type: EXPERIMENTAL
Intervention: Whole-grain oat intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faecalibacterium prausnitzii presence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Germ-free (GF) mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F. prausnitzii-monocolonized mice
Number of subjects: 0
Study: 33704027

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) Change Package
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 1200
Study: 33704071

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin 150 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin 300 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 33704074

Group type: EXPERIMENTAL
Intervention: Low vision reading rehabilitation using magnification for 3 weeks
Number of subjects: 150
Study: 33704077

Group type: EXPERIMENTAL
Intervention: Diabetes remote monitoring program facilitated by cellular-connected glucose meter and phone-based diabetes coaching provided by Livongo Health.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care (UC) before intervention.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Diabetes remote monitoring program after usual care (IV/UC).
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care before intervention (UC/IV).
Number of subjects: 119
Study: 33704444

Group type: EXPERIMENTAL
Intervention: ART (Antiretroviral Therapy)
Number of subjects: 2432

Group type: EXPERIMENTAL
Intervention: Non-detectable viral load
Number of subjects: 2432
Study: 33704458

Group type: EXPERIMENTAL
Intervention: Technician-scored stool consistency using the Bristol Stool Form Scale (BSFS)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Dietary intake of saturated fat
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Allostatic load (AL) scores
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Machine learning analyses
Number of subjects: 364
Study: 33705389

Group type: EXPERIMENTAL
Intervention: Glucotypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional measures of continuous glucose monitoring
Number of subjects: 0
Study: 33705565

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Oxytocin solution
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Prostaglandins
Number of subjects: 2348
Study: 33706339

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally followed by misoprostol 800 micrograms buccally
Number of subjects: 266
Study: 33706343

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-Releasing Intrauterine System (LNG-IUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no LNG-IUS placement)
Number of subjects: 0
Study: 33706813

Group type: EXPERIMENTAL
Intervention: Individualized, culturally appropriate computerized decision-aid (DA) for lupus patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Standardized capacity-building activities for lupus DA implementation
Number of subjects: 500
Study: 33707216

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (12 weeks, including individualized resistance and aerobic exercises, and telephone health calls for the first 6 weeks)
Number of subjects: 40
Study: 33707233

Group type: EXPERIMENTAL
Intervention: Intratumoral tilsotolimod (8 mg) with systemic ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intratumoral tilsotolimod
Number of subjects: 0
Study: 33707268

Group type: EXPERIMENTAL
Intervention: Paediatric lung ultrasound (LUS)
Number of subjects: 41
Study: 33707402

Group type: EXPERIMENTAL
Intervention: Fast Recovery Group (n = 19)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extended Recovery Group (n = 12)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Limited Recovery Group (n = 9)
Number of subjects: 40
Study: 33708373

Group type: EXPERIMENTAL
Intervention: ABCD3-I score
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: ABCD2 score
Number of subjects: 577
Study: 33708474

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Inappropriate low doses of NOACs
Number of subjects: 359
Study: 33708484

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly injections
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 33708520

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 33708641

Group type: EXPERIMENTAL
Intervention: Switching monopolar no-touch radiofrequency ablation (RFA)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional radiofrequency ablation (RFA)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Switching monopolar no-touch RFA
Number of subjects: 116
Study: 33708780

Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (LD-DAC, 5 mg/m²)
Number of subjects: 0
Study: 33708965

Group type: EXPERIMENTAL
Intervention: Docetaxel continuation maintenance (DCM) therapy
Number of subjects: 375

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 375
Study: 33709202

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue total score, symptom subscale, and impact subscale
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score thresholds
Number of subjects: 40
Study: 33709288

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 40
Study: 33709325

Group type: EXPERIMENTAL
Intervention: 600-µm corneal pre-cut
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single-plane stab-incision
Number of subjects: 24

Group type: COMPARATOR
Intervention: Stab incision group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pre-cut group
Number of subjects: 24
Study: 33709329

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 0
Study: 33709779

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 33709930

Group type: EXPERIMENTAL
Intervention: NASCITA cohort study with web-based system for data collection and monitoring
Number of subjects: 5166
Study: 33709945

Group type: EXPERIMENTAL
Intervention: Self-assessment web-based triage app for COVID-19 symptoms
Number of subjects: 13000000
Study: 33710029

Group type: EXPERIMENTAL
Intervention: Kinetic glomerular filtration rate formulas (including Jelliffe, Chen, Chiou and Hsu, Moran and Myers, Yashiro, Seelhammer, and Brater)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Urinary creatinine clearance
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Yashiro equation
Number of subjects: 57
Study: 33710399

Group type: EXPERIMENTAL
Intervention: Aripiprazole (first trimester exposure)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Control group (no atypical antipsychotic during pregnancy)
Number of subjects: 848
Study: 33710523

Group type: EXPERIMENTAL
Intervention: First/second-generation EGFR-tyrosine kinase inhibitors (1G/2G EGFR-TKIs)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Other systemic treatments
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Subsequent systemic treatment after progression on 1G/2G EGFR-TKIs
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Osimertinib after progression on 1G/2G EGFR-TKIs
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Testing for T790M mutation
Number of subjects: 141
Study: 33710614

Group type: COMPARATOR
Intervention: dupilumab
Number of subjects: 1262

Group type: COMPARATOR
Intervention: mepolizumab
Number of subjects: 1262

Group type: COMPARATOR
Intervention: omalizumab
Number of subjects: 1262
Study: 33710626

Group type: COMPARATOR
Intervention: Enteral zinc supplementation
Number of subjects: 482
Study: 33710976

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (3-6 mg/kg, single oral or intravenous dose)
Number of subjects: 32
Study: 33711074

Group type: EXPERIMENTAL
Intervention: TAK-003 (tetravalent live attenuated dengue vaccine)
Number of subjects: 0
Study: 33711699

Group type: EXPERIMENTAL
Intervention: Granulocyte-Colony Stimulating Factors (G-CSF)
Number of subjects: 2920

Group type: COMPARATOR
Intervention: No G-CSF
Number of subjects: 2920
Study: 33712086

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 6.25 mg/kg oral capsules twice daily for 6 weeks, potentially increasing to 12.5 mg/kg twice daily for another 6 weeks if pain is not adequately controlled
Number of subjects: 30
Study: 33712090

Group type: EXPERIMENTAL
Intervention: Attention Control Training (ACT) intervention, average 84 minutes of training over three visits.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eye-tracking data quality was moderate.
Number of subjects: 12
Study: 33712275

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) ultrastaging
Number of subjects: 30
Study: 33712377

Group type: EXPERIMENTAL
Intervention: ZNF804A genotype
Number of subjects: 72
Study: 33712437

Group type: EXPERIMENTAL
Intervention: MD ARC-520
Number of subjects: 8
Study: 33712505

Group type: EXPERIMENTAL
Intervention: RMW present (MIP <30 cmH2O)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: RMW present
Number of subjects: 366

Group type: COMPARATOR
Intervention: RMW absent
Number of subjects: 366
Study: 33712561

Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (EAW) training using a powered exoskeleton (ReWalk)
Number of subjects: 8
Study: 33712849

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg/day (3-day ramp up in cycle 1) plus azacitidine 75 mg/m2 on days 1-7 per 28-day cycle
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Venetoclax plus azacitidine
Number of subjects: 6
Study: 33713190

Group type: EXPERIMENTAL
Intervention: PET-positive nodules
Number of subjects: 32

Group type: COMPARATOR
Intervention: PET-negative nodules
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PET-positive nodules with benign nodule
Number of subjects: 32

Group type: COMPARATOR
Intervention: PET-negative nodule
Number of subjects: 32

Group type: COMPARATOR
Intervention: Thyroid nodules without suspicious ultrasonographic findings
Number of subjects: 32
Study: 33713216

Group type: EXPERIMENTAL
Intervention: HLX07 at 50 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HLX07 at 100 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HLX07 at 200 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HLX07 at 400 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HLX07 at 600 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HLX07 at 800 mg
Number of subjects: 19
Study: 33713409

Group type: EXPERIMENTAL
Intervention: Varenicline treatment
Number of subjects: 189

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 33713731

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 1803
Study: 33713742

Group type: EXPERIMENTAL
Intervention: Cisplatin at 30 mg/m² with adjuvant radiation therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cisplatin at 10 mg/m²
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cisplatin at 40 mg/m²
Number of subjects: 55
Study: 33714009

Group type: EXPERIMENTAL
Intervention: Olaparib alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Olaparib plus cisplatin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Olaparib plus durvalumab
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisplatin-containing chemoradiation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 70
Study: 33714271

Group type: EXPERIMENTAL
Intervention: Functional capacity of >4 MET
Number of subjects: 296

Group type: COMPARATOR
Intervention: Functional capacity of <4 MET
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Infrarenal cohort (>4 MET)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Infrarenal cohort (<4 MET)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Open surgical technique (<4 MET)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: >4 MET
Number of subjects: 296

Group type: COMPARATOR
Intervention: <4 MET
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 296
Study: 33714278

Group type: EXPERIMENTAL
Intervention: CAD screening procedure during the selection period (2008-2015)
Number of subjects: 90000

Group type: COMPARATOR
Intervention: No CAD screening
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: CAD screening procedure
Number of subjects: 90000
Study: 33714389

Group type: EXPERIMENTAL
Intervention: Combined NIRS and intravascular ultrasound
Number of subjects: 898
Study: 33714749

Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block (SNB)
Number of subjects: 25
Study: 33715033

Group type: EXPERIMENTAL
Intervention: Imaging modalities (including WBMRI)
Number of subjects: 79
Study: 33715160

Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 hyperimmune globulin (hIVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Convalescent plasma
Number of subjects: 0
Study: 33715620

Group type: EXPERIMENTAL
Intervention: eGDR tertile T3 (≤ 4.14 mg/kg/min, highest IR)
Number of subjects: 15773

Group type: COMPARATOR
Intervention: eGDR tertile T1 (≥ 5.35 mg/kg/min)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: eGDR in participants with no DKD
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: eGDR in participants with nonalbuminuric DKD
Number of subjects: 15773